Lupin is currently trading at Rs. 743.55, up by 4.15 points or 0.56% from its previous closing of Rs. 739.40 on the BSE.
The scrip opened at Rs. 739.50 and has touched a high and low of Rs. 746.75 and Rs. 739.35 respectively. So far 5936 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 752.15 and Rs. 678.65 respectively. The current market cap of the company is Rs. 33602.09 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin’s 100% subsidiary -- Lupin Diagnostics has launched its first Reference Laboratory in East India in Kolkata. The new Reference Laboratory at Kolkata has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, haematology, immunology and routine biochemistry.
The company is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region. These processing labs will be located in the cities of Siliguri, Berhampore, Asansol, Burdwan and Bankura in West Bengal, along with Guwahati (Assam), Patna (Bihar), Ranchi and Dhanbad (Jharkhand) and Bhubaneshwar (Orissa). These labs will be connected to Lupin’s franchise collection centers, LupiMitra. Lupin Diagnostics has more than 100 LupiMitra already enrolled for its East India operations.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India
